2023 World Conference on Lung Cancer (Posters)-P2.10. Comparative Effectiveness Analysis of Selpercatinib versus Standard Therapy in Patients with Non-small Cell Lung Cancer

P2.10. Comparative Effectiveness Analysis of Selpercatinib versus Standard Therapy in Patients with Non-small Cell Lung Cancer - PDF(Slides)

Back to course

Pdf Summary

This document is a summary of a study comparing the effectiveness of selpercatinib, a drug used for the treatment of non-small cell lung cancer (NSCLC), with standard therapies in patients with advanced NSCLC. The study utilized data from the LIBRETTO-001 trial, which is a phase I/II clinical trial of patients with NSCLC who have a particular genetic alteration called RET fusion.<br /><br />The study compared two groups of patients: those who received selpercatinib as their first-line treatment and those who received standard therapies as their first-line treatment. The outcomes assessed included time to treatment discontinuation, time to next treatment or death, time to progression, and overall response rate. The results showed that patients treated with selpercatinib had longer median times to treatment discontinuation, next treatment or death, and progression compared to those treated with standard therapies. The overall response rate was also significantly higher in the selpercatinib group.<br /><br />The study concluded that selpercatinib treatment was associated with improved outcomes compared to standard therapies in the first-line setting. However, it should be noted that the data for the standard therapy group were obtained from medical records, which may introduce bias. Therefore, the results should be interpreted with caution.<br /><br />Overall, this study suggests that selpercatinib may be a more effective treatment option for patients with advanced NSCLC compared to standard therapies.

Asset Subtitle

Daniel Tan

Meta Tag

Speaker Daniel Tan

Topic Metastatic NSCLC: Targeted Therapy - FUSIONS

Keywords

selpercatinib

non-small cell lung cancer

NSCLC

LIBRETTO-001 trial

RET fusion

first-line treatment

standard therapies

time to treatment discontinuation

time to next treatment or death

overall response rate